Should I buy or sell Vaxcyte stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCVX shares. View PCVX analyst ratings or view top-rated stocks .

What is Vaxcyte's stock price target for 2024?

4 brokerages have issued 1 year price targets for Vaxcyte's stock. Their PCVX share price targets range from $69.00 to $95.00. On average, they predict the company's share price to reach $78.50 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts .

How have PCVX shares performed in 2024?

Vaxcyte's stock was trading at $62.80 on January 1st, 2024. Since then, PCVX shares have decreased by 1.9% and is now trading at $61.59. View the best growth stocks for 2024 here .

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PCVX earnings forecast .

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) posted its earnings results on Tuesday, February, 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.93. During the same quarter in the previous year, the company earned ($0.73) EPS.

What ETFs hold Vaxcyte's stock?

ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Amplify Treatments, Testing and Advancements ETF (GERM) , Alger Mid Cap 40 ETF (FRTY) , Harbor Health Care ETF (MEDI) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Fidelity Disruptive Medicine ETF (FMED) , Principal Healthcare Innovators ETF (BTEC) and SPDR S&P Biotech ETF (XBI) .

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA) , Twilio (TWLO) , Boeing (BA) , Overstock.com (OSTK) , Pure Storage (PSTG) , QUALCOMM (QCOM) , Riot Platforms (RIOT) , American Tower (AMT) , Avid Technology (AVID) and CalAmp (CAMP) .

When did Vaxcyte IPO?

Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Andrew Guggenhime , Elvia Cowan, Grant Pickering , Heath Lukatch , Jane Wright-Mitchell , Jeff Fairman , Jim Wassil , Mikhail Eydelman and Paul Sauer . View institutional ownership trends .

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PCVX

Vaxcyte (PCVX) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free PCVX Stock Alerts

$61.05

+0.43 (+0.71%)

(As of 10:39 AM ET)

Compare

Today's Range: $60.46
▼
$61.92
50-Day Range: $60.62
▼
$81.05
52-Week Range: $41.57
▼
$82.04

Volume: 130,305 shs
Average Volume: 823,067 shs
Market Capitalization: $6.64 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $78.50

Get Vaxcyte alerts:

Vaxcyte MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 27.5% Upside
$78.50 Price Target
Short Interest: Bearish
7.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Selling Shares
$6.94 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.18) to ($4.51) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

763rd out of 918 stocks

Biological Products, Except Diagnostic Industry

133rd out of 154 stocks

3.5

Analyst's Opinion

Consensus Rating
Vaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vaxcyte has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.59% of the outstanding shares of Vaxcyte have been sold short.
Short Interest Ratio / Days to Cover
Vaxcyte has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in Vaxcyte has recently decreased by 3.84%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Vaxcyte does not currently pay a dividend.
Dividend Growth
Vaxcyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PCVX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Vaxcyte this week, compared to 3 articles on an average week.
Search Interest
4 people have searched for PCVX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,940,475.00 in company stock.
Percentage Held by Insiders
Only 3.60% of the stock of Vaxcyte is held by insiders.
Percentage Held by Institutions
96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vaxcyte are expected to decrease in the coming year, from ($4.18) to ($4.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaxcyte is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaxcyte is -14.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaxcyte has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Vaxcyte Stock (NASDAQ:PCVX)

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PCVX Stock News Headlines

March 28, 2024 | insidertrades.com

Grant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

March 22, 2024 | insidertrades.com

Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

April 19, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…

April 14, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - PCVX

April 11, 2024 | americanbankingnews.com

Vaxcyte (NASDAQ:PCVX) Given "Buy" Rating at Needham & Company LLC

April 10, 2024 | msn.com

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says

April 2, 2024 | globenewswire.com

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 20, 2024 | finance.yahoo.com

Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares

April 19, 2024 | WealthPress (Ad)

Chances are you know the firms on this list

March 16, 2024 | ca.finance.yahoo.com

PCVX Jul 2024 70.000 put

March 16, 2024 | ca.finance.yahoo.com

PCVX Apr 2024 80.000 put

March 16, 2024 | finance.yahoo.com

PCVX Apr 2024 100.000 call

March 12, 2024 | msn.com

Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday

March 4, 2024 | finanznachrichten.de

Vaxcyte, Inc.: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

March 4, 2024 | globenewswire.com

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vaxcyte Amid Anticipation of Transformative VAX-31 Data Release

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vaxcyte on Strong Vaccine Candidate Prospects and Upward Financial Projections

February 28, 2024 | markets.businessinsider.com

Vaxcyte’s VAX-31 Poised for Market Leadership: Shrader’s Bullish Forecast and Price Target Update

February 28, 2024 | markets.businessinsider.com

TD Cowen Remains a Buy on Vaxcyte (PCVX)

February 28, 2024 | finance.yahoo.com

Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript

February 27, 2024 | seekingalpha.com

Vaxcyte, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 27, 2024 | globenewswire.com

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 26, 2024 | benzinga.com

Vaxcyte Stock (NASDAQ:PCVX), Short Interest Report

February 25, 2024 | insidermonkey.com

5 Best Russell 2000 Stocks To Buy According To Hedge Funds

February 17, 2024 | finance.yahoo.com

PCVX Apr 2024 50.000 call

February 17, 2024 | finance.yahoo.com

PCVX Sep 2024 40.000 put

February 16, 2024 | finance.yahoo.com

PCVX Mar 2024 90.000 call

See More Headlines

Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:PCVX
CUSIP: N/A
CIK: 1649094
Web: www.vaxcyte.com
Phone: 650-837-0111
Fax: N/A
Employees: 254
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $78.50
High Stock Price Target: $95.00
Low Stock Price Target: $69.00
Potential Upside/Downside: +29.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-402,270,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.04%
Return on Assets: -29.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.54
Quick Ratio: 7.54

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.04 per share
Price / Book: 4.65

Miscellaneous

Outstanding Shares: 108,760,000
Free Float: 104,505,000
Market Cap: $6.59 billion
Optionable: Optionable
Beta: 0.89

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Grant E. Pickering M.B.A. (Age 56)
Co-Founder, CEO & Director
Comp: $1.1M
Mr. Andrew L. Guggenhime M.B.A. (Age 56)
President & CFO
Comp: $839.65k
Mr. James Wassil M.B.A. (Age 55)
M.S., Executive VP & COO
Comp: $826.3k
Mr. Paul W. Sauer M.B.A. (Age 63)
Senior Vice President of Process Development & Manufacturing
Comp: $608.96k
Dr. Ashish Khanna M.B.A. (Age 52)
Ph.D., Co-Founder
Dr. Jeff Fairman Ph.D. (Age 60)
Co-Founder & VP of Research
Ms. Elvia Cowan (Age 51)
Senior VP of Finance & Principal Accounting Officer
Ms. Janet Graesser
Senior Vice President of Corporate Communications & Investor Relations
Ms. Whitney Jones
Chief People Officer
Mr. Harp Dhaliwal M.B.A. (Age 51)
Senior Vice President of Commercial Manufacturing & Supply Chain
Comp: $146.48k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings or view top-rated stocks.
What is Vaxcyte's stock price target for 2024?: 4 brokerages have issued 1 year price targets for Vaxcyte's stock. Their PCVX share price targets range from $69.00 to $95.00. On average, they predict the company's share price to reach $78.50 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price.
View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts.
How have PCVX shares performed in 2024?: Vaxcyte's stock was trading at $62.80 on January 1st, 2024. Since then, PCVX shares have decreased by 1.9% and is now trading at $61.59.
View the best growth stocks for 2024 here.
When is Vaxcyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PCVX earnings forecast.
How were Vaxcyte's earnings last quarter?: Vaxcyte, Inc. (NASDAQ:PCVX) posted its earnings results on Tuesday, February, 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.93. During the same quarter in the previous year, the company earned ($0.73) EPS.
What ETFs hold Vaxcyte's stock?: ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Amplify Treatments, Testing and Advancements ETF (GERM), Alger Mid Cap 40 ETF (FRTY), Harbor Health Care ETF (MEDI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC) and SPDR S&P Biotech ETF (XBI).

What other stocks do shareholders of Vaxcyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).
When did Vaxcyte IPO?: Vaxcyte (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.
Who are Vaxcyte's major shareholders?: Vaxcyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Andrew Guggenhime, Elvia Cowan, Grant Pickering, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman and Paul Sauer.
View institutional ownership trends.
How do I buy shares of Vaxcyte?: Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCVX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial